Management ChangeApr 30, 2026, 05:12 PM
PHGE Appoints New CEO & CFO; Board Reconstituted
AI Summary
BiomX Inc. filed an amendment to its 2025 Form 10-K to include previously omitted Part III information, updated certifications, and revised cover page details. The filing announces significant management changes, including the appointment of Michael Oster as CEO effective March 4, 2026, and David Rokach as CFO effective February 27, 2026. This follows the resignations of former CEO Jonathan Solomon, former CFO Marina Wolfson, and Chief Development Officer Dr. Merav Bassan. Additionally, several directors resigned, leading to a reconstituted Board, and the filing details executive and director compensation for fiscal year 2025.
Key Highlights
- Michael Oster appointed CEO of BiomX Inc. effective March 4, 2026.
- David Rokach appointed CFO of BiomX Inc. effective February 27, 2026.
- Former CEO Jonathan Solomon resigned March 4, 2026, with 2025 compensation of $1,375,022.
- Former CFO Marina Wolfson and Chief Development Officer Dr. Merav Bassan resigned February 24, 2026.
- Multiple directors, including Dr. Russell Greig, Susan Blum, Jesse Goodman, Jonathan Leff, Greg Merril, Dr. Alan Moses, Edward Williams, and Amir Shalom, resigned in Feb/March 2026.
- The Board is now comprised of Reuven Yeganeh, Liat Bidas, Guy Arieli, and Ran Shaked, with three independent directors.
- Total compensation for non-employee directors in fiscal year 2025 was $639,374.